Company highlights key factors expected to impact Q4 COVID-19 testing during UBS analyst event
COVID-19 has impacted diagnostic volumes, mix and reimbursement for a variety of diagnostic providers. As the nation transitions into fall, new challenges will arise for the laboratory industry as students go back to school and flu season hits its peak. XIFIN CEO Lâle White and Kyle Fetter, Executive Vice President & General Manager of Diagnostic Services, recently joined healthcare analysts from UBS for an audio conference to discuss the key factors that will impact COVID testing volumes heading into the fall, analyze activity across its customer lab networks, and provide an update on payor reimbursement activity.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200922005762/en/
(Graphic: Business Wire)
“Six months into the COVID-19 pandemic, diagnostic labs nationwide continue to see high testing volumes. Early implementation of rapid diagnostics testing could positively impact overall testing